Fastlane, the South Korean start-up behind Yeoshin Ticket (YeoTi), landed $7.3 million in Series C funding to fuel growth.WHO: Founded in 2016 by Fastlane, Yeoshin Ticket (YeoTi) is a platform that provides information and booking services for aesthetic treatments. It functions as a marketplace connecting users with dermatology clinics, offering features like price comparisons, customer reviews, and discounted treatments.IN THEIR OWN WORDS: Fastlane CEO Seungwoo Son said, “We are preparing for a KOSDAQ listing in the first half of 2027 by strengthening our internal organization and expanding our business portfolio. Through the IPO, we aim to accelerate global expansion, broaden our service regions and treatment categories, and continue driving sustainable growth.”DETAILS:Fastlane secured approximately $7.3 million (KRW 10 billion) in Series C funding structured as a pre-IPO investment. Investors included Korea Development Bank, T Investment, Comes Investment, iM Investment Partners, AFW Partners, Mobydick Asset Management, and Hill Spring Investment.The company has raised $19.2 million (KRW 26.3 billion) to date.The app recorded 3.6 million downloads, 850,000 members, and 530,000 monthly active users in the first half of 2025.Since last year, the company has launched global versions of the app in China, the United States, and Japan to capture international users.In December 2021, the company raised $10 million (KRW 12 billion) in Series B funding from investors including Korea Investment Partners, IMM Investment, and Shinhan Venture Investment.In April 2020, Fastlane raised $3 million (KRW 3.5 billion) in Series A funding.